Now Offering Telehealth Consultations - Call (951) 898-8515

Compounded Tirzepatide vial for medically supervised weight loss program

Tirzepatide

Regular price
$368.00
Sale price
$368.00

Tirzepatide Weight Loss Program — Slender Me Medical

Tirzepatide is a dual GIP/GLP-1 receptor agonist that, as part of a medically supervised program, may support meaningful weight reduction when combined with a reduced-calorie diet and increased physical activity.

At Slender Me Medical, our program is overseen by a licensed nurse practitioner. We provide compounded Tirzepatide through a SCRIPT-certified pharmacy, with a personalized step-up dosing protocol and ongoing clinical monitoring. Available via in-office visit or telehealth.

Step-Up Dosing Program

  • Month 1 (2.2mg): Starting dose — $368
  • Month 2 (4.4mg): Titration phase — $458
  • Month 3 (6.6mg): Continued titration — $528
  • Month 4 (8.8mg): Therapeutic range — $633
  • Month 5 (11mg): Maintenance dose — $638

New patients: select Month 1. Our clinical team will assess your eligibility and guide your dosing plan.

🔬 Maximize Your Results with a CGM

Want to take your Tirzepatide results to the next level? We highly recommend adding a Continuous Glucose Monitor (CGM) to your program. A CGM tracks your blood sugar in real time — showing you exactly how food, sleep, exercise, and your medication are affecting your body. Patients who combine GLP-1 therapy with CGM monitoring make smarter food choices, stay more motivated, and achieve significantly better outcomes.

➡ Learn more about our CGM Program →

Important Safety Information

  • Tirzepatide is a prescription medication. A clinical consultation and eligibility screening are required prior to dispensing.
  • This product is a compounded preparation and has not been approved by the FDA. Compounded medications are not subject to FDA pre-market approval for safety, efficacy, or manufacturing quality.
  • Common side effects may include nausea, vomiting, diarrhea, constipation, and decreased appetite.
  • Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or breastfeeding.
  • If lab work is required by your provider, it will be billed separately.
  • Individual results vary. Weight loss outcomes depend on adherence to the program, diet, and physical activity.
  • This page is for informational purposes only and does not constitute medical advice.

After purchase, our clinical team will contact you to verify eligibility, complete your intake, and coordinate delivery or your visit. Purchase does not guarantee dispensing of medication.